Figure 6.

The content of lipids containing C16:0 (palmitic acid) components in HepaRG cells, detected using lipidomics. (A) Nonisotopically labeled palmitic acid was administered to induce lipid toxicity in HepaRG cells; (B) C13-isotope-labeled palmitic acid was administered to cells. The relative abundance of a class of lipids in the model group and the treatment group was obtained by normalizing the content in the control group. The Control group was untreated cells; the Model group was cells administered 0.2 mM palmitic acid for 24 h; the Treatment group was cells administered 0.2 mM palmitic acid plus 0.25 mM magnesium isoglycyrrhizinate for 24 h. Data are expressed as the mean ± SD (n = 5). In the statistical analysis carried out between the other groups and the control group, “ns” means p > 0.05, * p < 0.05; ** p < 0.01, *** p < 0.001; **** p < 0.0001. In the statistical analysis carried out between the Treatment group and Model group, ^### p < 0.001. DAG (C16:0 incorporation): the total content of a series of diglycerides containing C16:0; TAG: Triglyceride; PA: Phosphatidic acid; PC: Phosphatidylcholine; PS: Phosphatidylserine; PE: phosphatidylethanolamine; LPE: Lysophosphatidylethanolamine; LPI: Lysophosphatidylinositol. C¹³-DAG (16:0/16:0): one C¹³-isotope labelled diglyceride containing two molecules of C16:0; C¹³-PA (16:0/16:0): one C¹³-isotope labelled phosphatidic acid containing two molecules of C16:0.